.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents and clinical trials in dozens of countries
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Merck
Boehringer Ingelheim
Deloitte
UBS
US Department of Justice
AstraZeneca
Moodys
Harvard Business School
Queensland Health

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,247,318

« Back to Dashboard

Which drugs does patent 7,247,318 protect, and when does it expire?


Patent 7,247,318 protects APTENSIO XR and is included in one NDA. There have been four Paragraph IV challenges on Aptensio XR.

This patent has nine patent family members in eleven countries.

Summary for Patent: 7,247,318

Title:Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
Inventor(s): Krishnamurthy; Thinnayam N. (Ontario, CA), Darke; Andrew (Ontario, CA)
Assignee: Purdue Pharma (Pickering, Ontario, CA)
Application Number:10/156,622
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-001Apr 17, 2015RXYesNo7,247,318► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-002Apr 17, 2015RXYesNo7,247,318► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-003Apr 17, 2015RXYesNo7,247,318► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-004Apr 17, 2015RXYesNo7,247,318► SubscribeY
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-005Apr 17, 2015RXYesNo7,247,318► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,247,318

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,066,869Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations► Subscribe
6,419,960 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations► Subscribe
8,580,310Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations► Subscribe
7,438,930Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,247,318

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2224740► Subscribe
Canada2355854► Subscribe
Germany69917937► Subscribe
Denmark1143937► Subscribe
European Patent Office1143937► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
McKesson
Fish and Richardson
UBS
Johnson and Johnson
Deloitte
Covington
AstraZeneca
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot